Patent icon

Patent

Treatment for Dupuytren's disease

Documentation:
Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-alpha antagonist. TNF-alpha antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such ascollagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Kennedy Institute for Rheumatology
Oxford college:
Wolfson College
Role:
Author
ORCID:
0000-0002-9579-9411
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Kennedy Institute for Rheumatology
Role:
Author
ORCID:
0000-0002-8813-2977
Publication date:
2013-10-31
Event end date:
2031-10-31
Territory:
USA
Patent number:
US20130287760A1
Language:
English
Keywords:
Pubs id:
1108394
Local pid:
pubs:1108394
Deposit date:
2020-06-02

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP